The FDA today granted accelerated approval to idarucizumab, which is intended for patients who require emergency reversal of dabigatran’s blood-thinning effects. Idarucizumab (Praxbind, Boehringer ...

NEW ORLEANS, LA—Administration of idarucizumab induces rapid and complete reversal of the anticoagulant effects of dabigatran, both in patients presenting with uncontrolled bleeding and in those ...

Tiotropium as Asthma Add-On Treatment Shows Promise Boehringer Ingelheim announced results from an interim analysis of the Phase 3 RE-VERSE AS patient study with idarucizumab for urgent reversal of ...

Idarucizumab, a humanized monoclonal antibody fragment designed to bind strongly to dabigatran, rapidly and safely neutralizes the effects of the anticoagulant, according to final results from the ...

Tiotropium as Asthma Add-On Treatment Shows Promise The Food and Drug Administration (FDA) has granted Priority Review to the Biologics License Application (BLA) for idarucizumab (Boehringer Ingelheim ...

The U.S. Food and Drug Administration today granted accelerated approval to Praxbind (idarucizumab) for use in patients who are taking the anticoagulant Pradaxa (dabigatran) during emergency ...

RIDGEFIELD, Conn., May 4, 2018 /PRNewswire/ -- Today, Boehringer Ingelheim announced that Praxbind® (idarucizumab), a specific reversal agent for Pradaxa® (dabigatran etexilate mesylate), is now ...

TORONTO, ON — A real-world clinical test of idarucizumab (Boehringer Ingelheim) shows the agent safely and effectively reverses the anticoagulant effect of the direct oral thrombin inhibitor ...

Here are two small but important changes in the anticoagulation field: FDA approves new product for urgent reversal of anticoagulation. The FDA yesterday approved Kcentra (Prothrombin Complex ...

BERLIN — Using the monoclonal antibody reversal agent idarucizumab (Praxbind, Boehringer Ingelheim), researchers have shown rapid, complete, and sustained reversal of dabigatran etexilate (Pradaxa, ...

INGELHEIM, Germany--(BUSINESS WIRE)--Boehringer Ingelheim GmbH announced the U.S. Food and Drug Administration (FDA) granted approval of Praxbind ® (idarucizumab). 4 Praxbind ® is indicated for ...